![](/fileadmin/_processed_/csm_EBC_c_CDC_7b5c041c11.png)
Hornet Therapeutics reports first data of EBV-triggered disease blocker
Hornet Therapeutics Ltd that was spun out in 2020 from the group of Christoph Hess (now University Cambridge) at University Basel, has...
![](/fileadmin/_processed_/csm_Evotec_HQ_516a5db450.jpg)
Consortium led by Evotec enters obesity drug space
The newly formed strategic partnership between Evotec SE, Inserm, Lille University Hospital and Inserm Transfert aims to identify novel multimodal...
![](/fileadmin/_processed_/csm_SFactory01_Launch_044ec847f4.png)
Solar Foods starts Factory01
Following market authorisation in Singapore two years ago, the Finnish company Solar Foods Oy and the Japanese food giant Ajinomoto Group want to...
![](/fileadmin/_processed_/csm_Microglia_and_neurons_c__Gary_Shaw_ed89bb0973.jpg)
Researchers identify blockers of CNS effects of PD1 cancer therapy
In mouse models, a group headed by Marco Prinz from University Freiburg demonstrated that adverse side effects of immune cancer therapies with PD1...
![](/fileadmin/_processed_/csm_RNF31_Pub_domain__c__RCBS_protein_data_base_62ddf70879.jpg)
Flindr Therapeutics BV secures €20m Series A financing
The Series A financing was led by V-Bio Ventures and an international syndicate that includes Johnson & Johnson Innovation – JJDC, Inc., QBIC...
![](/fileadmin/_processed_/csm_RNA_IQVIA_18a4c7238b.png)
Wacker Chemie AG opens €100m RNA manufacturing site
With a new production facility, which Wacker Chemie subsidiary Wacker Biotech calls an RNA competence centre and whose construction costs are...
![](/fileadmin/_processed_/csm_Biotalys_platform_b35a9cfabc.png)
Biotalys starts field testing for biofungicide
The protein-based biofungicide is under development of the company’s Agrobody technology platform for sustainable biocontrols as an alternative...